- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 7/06 - Antianaemics
Patent holdings for IPC class A61P 7/06
Total number of patents in this class: 1562
10-year publication summary
|
38
|
59
|
60
|
114
|
101
|
131
|
158
|
179
|
123
|
31
|
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Acceleron Pharma Inc. | 365 |
46 |
| Agios Pharmaceuticals, Inc | 200 |
29 |
| Daiichi Sankyo Company, Limited | 1829 |
29 |
| Global Blood Therapeutics, Inc. | 180 |
21 |
| Vifor (International) AG | 143 |
21 |
| The Children's Hospital of Philadelphia | 716 |
14 |
| Children's Medical Center Corporation | 1780 |
14 |
| Takeda Pharmaceutical Company Limited | 2961 |
13 |
| FibroGen, Inc. | 186 |
13 |
| Akebia Therapeutics, Inc. | 115 |
12 |
| Pharmacosmos Holding A/S | 119 |
12 |
| Novartis AG | 11238 |
11 |
| Amgen Inc. | 3779 |
11 |
| Epizyme, Inc. | 383 |
11 |
| Sunshine Lake Pharma Co., Ltd. | 542 |
11 |
| The Regents of the University of California | 18943 |
10 |
| Sichuan Inlu Weite Pharmaceutical Technology Co., Ltd. | 20 |
10 |
| Keros Therapeutics, Inc. | 53 |
10 |
| Ajinomoto Co., Inc. | 2337 |
9 |
| Celgene Corporation | 1412 |
9 |
| Other owners | 1246 |